Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles ...